| name | nd-t2d-oad-selector |
| description | Select oral and injectable glucose-lowering agents for a newly diagnosed patient with type 2 diabetes using a compelling-indication hierarchy (heart failure → ASCVD → DKD → obesity) followed by glucose-pattern matching. Incorporates modern GLP-1 receptor agonists — Ozempic (semaglutide SC, T2D), Mounjaro (tirzepatide), and Wegovy/Noveltreat (semaglutide 2.4 mg, obesity). Use when a clinician asks "what drug to start for newly diagnosed T2D", "which OAD to use", "first-line diabetes medication", "SGLT2i vs GLP-1 in new T2D", or presents a newly diagnosed T2D patient needing a personalised medication plan. |
OAD Selection — Newly Diagnosed Type 2 Diabetes
Confirm Eligibility First
This tool is for newly diagnosed, non-insulin-requiring T2DM.
Stop here and initiate insulin instead if any of the following apply:
- HbA1c ≥10%
- Any glucose >400 mg/dL
- FBS >200 AND PP2BS ≥300 mg/dL
- Osmotic symptoms (polyuria, polydipsia, weight loss) or ketosis
- GAD antibody positive, OR random C-peptide <0.6 ng/mL with glucose 70–300 mg/dL
Also excluded: pregnancy, age <18, glucocorticoid-induced hyperglycaemia, eGFR <30.
Step 1 — Metformin (Universal First Line)
Tab Metformin SR/ER 1 g OD after breakfast
Skip only if: eGFR <30.
Always co-prescribe Methylcobalamin 1000 mcg OD after lunch with metformin.
Expected HbA1c reduction: ~0.8%
Step 2 — Compelling Indication Hierarchy
Work through A → D in order. Stop at the first that applies and add the indicated drug.
A. Heart Failure
→ Add an SGLT2 inhibitor (proven HF mortality benefit)
| Drug | Dose | Trial |
|---|
| Empagliflozin | 25 mg OD morning | EMPEROR-Reduced/Preserved |
| Dapagliflozin | 10 mg OD morning | DAPA-HF |
B. Established ASCVD or High CV Risk
High CV risk = age >55 with ≥2 of: hypertension, overweight/obesity, smoking, LDL ≥100 mg/dL, UACR >30 mg/g
If open to injectable → GLP-1 RA first (proven CV benefit):
| Drug | Starting dose | Titration | Max | Trial |
|---|
| Ozempic (semaglutide SC) | 0.25 mg SC weekly × 4 wk | → 0.5 mg × 4 wk | → 1 mg weekly | SUSTAIN-6 |
| Dulaglutide | 0.75 mg SC weekly | Fixed | 1.5 mg weekly | REWIND |
If not open to injectable → SGLT2 inhibitor:
- Empagliflozin 25 mg OD or Dapagliflozin 10 mg OD
If both GLP-1 RA and SGLT2i contraindicated:
- Pioglitazone 15 mg OD evening (PROACTIVE — CV benefit signal in T2D)
- Skip if: heart failure, BMI >27, macular oedema, retinopathy not assessed
C. Diabetic Kidney Disease (eGFR <60 or UACR >30 mg/g)
→ SGLT2 inhibitor first (proven renal benefit):
- Dapagliflozin 10 mg OD (DAPA-CKD)
- Empagliflozin 10 mg OD (EMPA-KIDNEY)
If SGLT2i contraindicated:
- Ozempic (semaglutide SC) 0.25 → 0.5 → 1 mg SC weekly (FLOW trial — renal benefit)
D. Obesity (BMI ≥30, or BMI ≥27 with ≥1 comorbidity)
Rank by degree of weight loss needed and injectable preference:
| Choice | Drug | Starting dose | Titration to maintenance |
|---|
| 1st — best glucose + weight | Mounjaro (tirzepatide) | 2.5 mg SC weekly | ↑ 2.5 mg every ≥4 wk → max 15 mg |
| 2nd — strong weight + glucose | Wegovy / Noveltreat (semaglutide 2.4 mg) | 0.25 mg SC weekly | → 0.5 → 1 → 1.7 → 2.4 mg (every 4 wk) |
| 3rd — not open to injectable | Dapagliflozin 10 mg or Canagliflozin 300 mg OD | — | — |
12-week continuation rule (Wegovy/Noveltreat): reassess at week 12 on maintenance dose. Discontinue if no meaningful BMI improvement.
Mounjaro 2.5 mg note: initiation dose only — not for glycaemic control. First therapeutic dose is 5 mg.
Step 3 — Still Above HbA1c Target? Match the Glucose Pattern
Calculate: Delta = PP2BS − FBS (mg/dL)
Delta >60 → Post-meal predominant
| Preference | Drug | Dose |
|---|
| Open to multiple pills | Acarbose | 50 mg TDS immediately before meals |
| Not open to multiple pills | Sitagliptin | 100 mg OD after breakfast |
| AGI contraindicated + open to pills | Repaglinide | 0.5 mg TDS immediately before meals |
⚠️ Do NOT add a DPP-IV inhibitor if already on a GLP-1 RA — redundant mechanisms, no additive benefit.
⚠️ Saxagliptin + heart failure — avoid. Use Sitagliptin instead.
Alpha-glucosidase inhibitors (acarbose) contraindicated if eGFR <25.
Delta ≤60 → Fasting predominant
| Drug | Dose | Note |
|---|
| Gliclazide XR (preferred) | 60 mg OD, 30 min after breakfast | Lower hypo risk than glimiperide |
| Glimiperide | 1 mg OD, 30 min after breakfast | Alternative |
Sulphonylurea contraindicated if: eGFR <15, moderate-to-severe frailty
If SU contraindicated → Pioglitazone 15 mg OD evening (if not already given)
If pioglitazone also contraindicated → Add Basal Insulin:
- Degludec at 10 pm (flexible timing — preferred for shift workers)
- Glargine at 10 pm (fixed timing)
- NPH at 10 pm (budget)
Starting dose: (FBS − 50) ÷ 10 units
Step 4 — Neuropathy Add-ons
All patients on metformin → Methylcobalamin 1000 mcg OD (already covered in Step 1).
If painful diabetic peripheral neuropathy is present, add:
- Pregabalin SR 75 mg at 7–8 pm (1–2 h before bedtime)
- Plus, if no ASCVD + BMI normal: Duloxetine 20 mg at bedtime (titrate to 60–120 mg)
- If ASCVD present or BMI >30: Alpha Lipoic Acid 600 mg OD after lunch (use instead of Duloxetine)
GLP-1 RA Contraindications (all agents)
- Personal or family history of MTC or MEN-2
- Pancreatitis history (absolute for Noveltreat; strong caution for Ozempic/Mounjaro)
- Severe gastroparesis
- BMI <19 (underweight)
- Pregnancy
- Do not combine with another GLP-1 RA or DPP-IV inhibitor
SGLT2i Contraindications
- eGFR <25
- Ketosis or osmotic symptoms at presentation
- Active genitourinary infection
- BMI <19
- Severe frailty
Key Drug Interactions
| Combination | Action |
|---|
| GLP-1 RA + sulphonylurea | Reduce SU dose at initiation → glp1-insulin-su-dose-reduction |
| GLP-1 RA + basal insulin | Reduce insulin by ~20% at initiation |
| Mounjaro + oral contraceptive | Non-oral or barrier contraception for 4 wk after each dose step → glp1-oral-contraceptive-interaction |
| DPP-IV + GLP-1 RA | Avoid — stop DPP-IV when adding GLP-1 RA |
Clinical Guardrails
- Ozempic vs Wegovy/Noveltreat — same molecule (semaglutide), different indication and max dose. Ozempic = T2D glycaemic control, max 1 mg weekly. Wegovy/Noveltreat = obesity, max 2.4 mg weekly. Never co-prescribe.
- Mounjaro 2.5 mg = tolerability dose, not a therapeutic dose. Expect glycaemic benefit from 5 mg onwards.
- Retinopathy + pioglitazone — always assess retinal status before prescribing; can worsen macular oedema.
- Perioperative GLP-1 RA — hold before procedures under GA/sedation. See
glp1-perioperative-aspiration.
Cross-Reference Skills
| Need | Skill |
|---|
| GI side-effect management | glp1-gi-ae-symptom-advisor, glp1-dose-escalation-troubleshooter |
| Pancreatobiliary monitoring | glp1-pancreatobiliary-risk-monitor |
| Perioperative decisions | glp1-perioperative-aspiration |
| SU/insulin dose reduction | glp1-insulin-su-dose-reduction |
| Mounjaro full prescribing | mounjaro-prescribing-guide |
| Wegovy/Noveltreat prescribing | wegovy-prescribing-guide, noveltreat-prescribing-guide |
| DKD staging | nd-t2d-dkd-classifier (coming) |
| HbA1c target | nd-t2d-hba1c-target (coming) |
Source
Diabetology.co.in Newly Diagnosed T2DM Algorithm (Lakhani O). Evidence base: ADA Standards of Care 2024; EMPA-REG OUTCOME, EMPEROR; DAPA-HF, DAPA-CKD; EMPA-KIDNEY; SUSTAIN-6; FLOW; REWIND; SURPASS 1–5; STEP 1–4; SURMOUNT 1–4.
